RINGPU(300119) 证券时报网·2025-04-07 02:09Core Insights - The company reported a revenue of 3.07 billion yuan, representing a year-on-year growth of 13.32%, and a net profit of 301 million yuan with a basic earnings per share of 0.65 yuan [1] Group 1: Product Development and Innovation - The company has developed a diverse product matrix with 587 products, including 122 biological products, 216 chemical drug formulations, and 102 veterinary medicines, covering major animal diseases in livestock [2] - The company invested 238 million yuan in R&D, accounting for 7.76% of its revenue, focusing on third-generation vaccines and new drug development [2] - The company has received 10 new veterinary drug registration certificates and holds 330 authorized patents, including 226 invention patents [2] Group 2: New Growth Opportunities - The company is expanding into pet medicine, synthetic biology, and international markets, with a product lineup that includes vaccines, drugs, and health products for pets [3] - Collaborations with research institutions are underway to promote the industrialization of synthetic biology projects, contributing to the green development of animal health and farming [3] - The company has been recognized for its synthetic biology project, which aims to transform the veterinary drug industry [3] Group 3: International Expansion - The company is actively pursuing an international strategy, registering 35 products in seven countries, including Indonesia and Sri Lanka [4] - The company’s production facilities have passed GMP certification in Indonesia and Thailand, laying a solid foundation for global expansion and international brand development [4]